Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batoclimab (HBM9161) in generalized myasthenia gravis
NCT04346888Phase 2Completed
- Sponsor
- Harbour BioMed
- Start
- Jul 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of batoclimab in myasthenia gravis (MG) (3 arms), sponsored by Harbour BioMed. Primary endpoint: Myasthenia Gravis Activities of Daily Living at Day 43. Started Jul 2020; status: completed.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04346888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346888.